Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out

Brain Hemorrhage – Pipeline Review, H1 2012

VIEWS: 5 PAGES: 41

Brain Hemorrhage - Pipeline Review, H1 2012, provides an overview of the Brain Hemorrhage therapeutic pipeline. This report provides information on the therapeutic development for Brain Hemorrhage, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Brain Hemorrhage. 'Brain Hemorrhage - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

More Info
									               Brain Hemorrhage – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1827IDB
                                                                                             Publication Date: March 2012




Brain Hemorrhage – Pipeline Review, H1 2012                                                 GMDHC1827IDB / Pub March 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                           Page(1)
Brain Hemorrhage – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 4
    List of Figures ................................................................................................................................................................................ 4
Introduction......................................................................................................................................................................................... 5
    Global Markets Direct Report Coverage ........................................................................................................................................ 5
Brain Hemorrhage Overview .............................................................................................................................................................. 6
Therapeutics Development................................................................................................................................................................. 7
    An Overview of Pipeline Products for Brain Hemorrhage .............................................................................................................. 7
Brain Hemorrhage Therapeutics under Development by Companies ................................................................................................ 9
Brain Hemorrhage Therapeutics under Investigation by Universities/Institutes ................................................................................ 10
Late Stage Products ......................................................................................................................................................................... 12
    Comparative Analysis .................................................................................................................................................................. 12
Mid Clinical Stage Products.............................................................................................................................................................. 13
    Comparative Analysis .................................................................................................................................................................. 13
Early Clinical Stage Products ........................................................................................................................................................... 14
    Comparative Analysis .................................................................................................................................................................. 14
Pre-Clinical Stage Products.............................................................................................................................................................. 15
    Comparative Analysis .................................................................................................................................................................. 15
Brain Hemorrhage Therapeutics – Products under Development by Companies ............................................................................ 16
Brain Hemorrhage Therapeutics – Products under Investigation by Universities/Institutes.............................................................. 17
Companies Involved in Brain Hemorrhage Therapeutics Development ........................................................................................... 18
    Transition Therapeutics Inc. ........................................................................................................................................................ 18
Brain Hemorrhage – Therapeutics Assessment ............................................................................................................................... 19
    Assessment by Monotherapy Products ....................................................................................................................................... 19
    Assessment by Combination Products ........................................................................................................................................ 20
    Assessment by Route of Administration ...................................................................................................................................... 21
    Assessment by Molecule Type .................................................................................................................................................... 23
Drug Profiles..................................................................................................................................................................................... 25
    Deferoxamine Mesylate - Drug Profile ......................................................................................................................................... 25
         Product Description................................................................................................................................................................. 25
         Mechanism of Action ............................................................................................................................................................... 25
         R&D Progress ......................................................................................................................................................................... 25
    Rosuvastatin - Drug Profile .......................................................................................................................................................... 26
         Product Description................................................................................................................................................................. 26
         Mechanism of Action ............................................................................................................................................................... 26
         R&D Progress ......................................................................................................................................................................... 26
    Labetalol + Hydralazine + Enalapril - Drug Profile ....................................................................................................................... 27
         Product Description................................................................................................................................................................. 27
         Mechanism of Action ............................................................................................................................................................... 27
         R&D Progress ......................................................................................................................................................................... 27
    Cathflo Activase - Drug Profile..................................................................................................................................................... 29
         Product Description................................................................................................................................................................. 29



Brain Hemorrhage – Pipeline Review, H1 2012                                                                                                     GMDHC1827IDB / Pub March 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Brain Hemorrhage – Pipeline Review, H1 2012




         Mechanism of Action ............................................................................................................................................................... 29
         R&D Progress ......................................................................................................................................................................... 29
    Desmopressin Acetate - Drug Profile .......................................................................................................................................... 30
         Product Description.........
								
To top